Medication info
Levomos Tablet 2.5/40 Milligrams

Levomos Tablet 2.5/40 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletS-Amlodipine Besylate 2.5 Hydrate›3.74mg / 1 tablet
Manufacturer / importer
Ahn-Guk Pharmaceutical Co., Ltd.
Appearance
Light yellow round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201405840 · Approved 2014.12.10 · Insurance code 650204240

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine [amlodipine] or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Ahn-Guk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to adequately control blood pressure in patients with essential hypertension who find it difficult to treat with monotherapy using either S-Amlodipine (Amlodipine) or Olmesartan Medoxomil. It helps protect heart and vascular health and lowers the risk of complications through blood pressure management. Regular use can aid in blood pressure control and improve health.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine [amlodipine] or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Those allergic to any components of this medication, pregnant or breastfeeding women, patients with severe liver impairment or certain heart conditions, and patients undergoing renal dialysis should not take it. Patients with fluid or salt deficiency may experience hypotension, so their condition must be carefully monitored during initial doses, and appropriate measures should be taken if hypotension occurs. Patients with certain heart conditions should be cautious as they may experience sudden vasodilation leading to hypotension. Heart failure patients must use this medication cautiously, and renal function must be closely monitored in patients with impaired kidney function. Patients with reduced liver function may experience slower metabolism of this medication, thus should exercise caution when taking it. Side effects such as dizziness, headache, hypotension, edema, indigestion, and skin rash can occur while taking this medication, and if symptoms are severe, consulting a healthcare professional is necessary. This medication can interact with other antihypertensive drugs or certain medications, so any drugs being taken must be disclosed. Particularly, co-administration with grapefruit juice can cause excessive blood pressure-lowering effects and should be avoided. It poses risks to the fetus during pregnancy, so if pregnancy is planned or confirmed, discontinuation and a consultation with a physician are advised. For breastfeeding mothers, since this drug can be transmitted through breast milk potentially causing side effects in infants, it is recommended to stop breastfeeding or discontinue the medication. It is advisable not to administer this drug to children under 18 years as safety and efficacy have not been established. Elderly patients should start at a lower dose and be monitored closely due to potential decline in liver and kidney function. In cases of overdose, severe hypotension and vascular dilation may lead to tachycardia or decreased cardiac function, and immediate medical treatment is required. This medication should be stored away from direct sunlight and moisture, out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • decreased sensation
  • syncope
Show 71 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lumbago
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • weakness
  • facial edema
  • decreased potassium in blood
  • increased creatinine in blood
  • increased uric acid in blood
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • lumbago
  • bronchitis
  • increased creatine kinase
  • hematuria
  • hyperglycemia
  • hypertriglyceridemia
  • influenza-like symptoms
  • pharyngitis
  • rhinitis
  • sinusitis
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • elevated creatinine in blood
  • hair loss
  • itching
  • urticaria
  • autoimmune hepatitis
  • erythema
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. Proper storage can help preserve the effectiveness of the medication for a longer duration.

Appearance and packaging

Appearance

Light yellow round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.